NCCN Guidelines® Insights: Hematopoietic Cell Transplantation, Version 3.2022

J Natl Compr Canc Netw. 2023 Feb;21(2):108-115. doi: 10.6004/jnccn.2023.0007.

Abstract

The NCCN Guidelines for Hematopoietic Cell Transplantation (HCT) provide an evidence- and consensus-based approach for the use of autologous and allogeneic HCT in the management of malignant diseases in adult patients. HCT is a potentially curative treatment option for patients with certain types of malignancies; however, recurrent malignancy and transplant-related complications often limit the long-term survival of HCT recipients. The purpose of these guidelines is to provide guidance regarding aspects of HCT, including pretransplant recipient evaluation, hematopoietic cell mobilization, and treatment of graft-versus-host disease-a major complication of allogeneic HCT-to enable the patient and clinician to assess management options in the context of an individual patient's condition. These NCCN Guidelines Insights provide a summary of the important recent updates to the NCCN Guidelines for HCT, including the incorporation of a newly developed section on the Principles of Conditioning for HCT.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Graft vs Host Disease* / diagnosis
  • Graft vs Host Disease* / etiology
  • Graft vs Host Disease* / prevention & control
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Humans
  • Neoplasm Recurrence, Local
  • Transplantation Conditioning / adverse effects
  • Transplantation, Homologous